Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: Effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations

Arthritis and Rheumatism

Volumn 62, Issue 6, 2010, Pages 1803-1812

  Becker, Mara L ^a   Van Haandel, Leon ^b   Gaedigk, Roger ^a   Lasky, Andrew ^a   Hoeltzel, Mark ^a   Stobaugh, John ^b   Steven Leeder, J ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; METHOTREXATE; METHOTREXATE POLYGLUTAMATE;

ARTICLE; BLOOD SAMPLING; CELL LEVEL; CELL LYSATE; CHILD; COHORT ANALYSIS; ERYTHROCYTE; FEMALE; HUMAN; ION PAIR CHROMATOGRAPHY; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, REVERSE-PHASE; CLUSTER ANALYSIS; DRUG ADMINISTRATION ROUTES; HUMANS; INFANT; METHOTREXATE; PATIENT SELECTION; POLYGLUTAMIC ACID; SEVERITY OF ILLNESS INDEX;

EID: 77952903257     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27434     Document Type: Article

References (28)

1. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, Feitosa de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50: 2191-2201
2. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 2004;50:364-371 (Pubitemid 38198819)
3. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate: utilization of leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001;44: 1984-1992
4. Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004; 31:2501-2506 (Pubitemid 39603104)
5. Becker ML, Rose CD, Cron RQ, Sherry DD, Bilker WB, Lautenbach E. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol 2010;37:870-875
6. Guiterrez-Urena S, Molina JF, Garcia CO, Cuéllar ML, Espinoza LR. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:272-276 (Pubitemid 26065267)
7. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-2682 (Pubitemid 24006532)
8. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985;260:9720-9726
9. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2004;66:403-456
10. Chabner BA, Allegra CJ, Curt GA, Cleneninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate: is methotrexate a pro drug? J Clin Invest 1985;76:907-912
11. Schroder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1988;21:145-149 (Pubitemid 18087030)
12. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression: a role for BCRP in cellular folate homeostasis. J Biol Chem 2004;279:25527-25534 (Pubitemid 38756812)
13. Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1995;22:844-849
14. Ravelli A, Di Fuccia G, Molinaro M, Ramenghi B, Zonta L, Regazzi MB, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 1993;20: 1573-1577 (Pubitemid 24027335)
15. Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgewood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989;32:677-681 (Pubitemid 19179246)
16. Dervieux T, Furst D, Orentas Lein D, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-1185 (Pubitemid 41113353)
17. Dervieux T, Furst D, Orentas Lein D, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthetase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-2774 (Pubitemid 39209513)
18. Dervieux T, Kremer J, Orentas Lein D, Capps R, Barham R, Meyer G, et al. Contribution of common polymorphisms in reduced folate carrier and γ-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004;14:733-739 (Pubitemid 39552788)
19. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zheng M, Barclay ML, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58: 3299-3308
20. Stamp LK, O'Donnell JL, Chapman PT, Zheng M, Frampton C, James J, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 2009;60:2248-2256
21. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-392 (Pubitemid 38160763)
22. Garratt LC, Ortori CA, Tucker GA, Sabilitzky F, Bennett MJ, Barrett DA. Comprehensive metabolic profiling of mono- and polyglutamated folates and their precursors in plant and animal tissue using liquid chromatography/negative ion electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:2390-2398
23. Van Haandel L, Becker ML, Leeder JS, Williams TD, Stobaugh JF. A novel high-performance liquid chromatography/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells. Rapid Commun Mass Spectrom 2009;23:3693-3702
24. Dervieux T, Orentas Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003;49:1632-1641 (Pubitemid 37194217)
25. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-1209 (Pubitemid 27430130)
26. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active arthritis that has been unresponsive to conventional doses of methotrexate. Arthritis Rheum 2004;50:364-371
27. Alsulfyani K, Ortiz-Alvarez O, Cabral D, Tucker L, Petty R, Malleson P. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2003;31:179-182 (Pubitemid 38067542)
28. Everens WE, Schentag JJ, Jusko WJ, Harrison H, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 2nd ed. New York: Applied Therapeutics; 1986.